


Report of Uttar Pradesh Delegation

Participation in 6th CII Biotechnology Mission to USA

Bio-2007: Boston

NRIs Meet: Chicago

May 3 to May 12, 2007



Submitted by:
Department of Science & Technology
Government of Uttar Pradesh
UP Civil Secretariat
Lucknow

**Report of Uttar Pradesh Delegation
Which visited U.S.A
From 3rd May to 12th May, 2007
and participated in 6th CII Biotechnology
Mission, Bio-2007 at Boston, Massachusetts
and held meetings with NRIs at Chicago of Illinois, USA**

In order to show case the state of U.P. and its strengths in various areas of biotechnology particularly Pharma and Agribiotechnology including the bio fuels in general and Lucknow in particular and attract private investment from U.S. and other countries, U.P. Government participated in the **International and Convention exhibition held at Boston, U.S.A.** under the title **Bio-2007**. The delegation also joined the 6th Biotechnology Mission of Confederation of Indian Industries (CII) to U.S.A. along with Bio-2007.



In this delegation from the Government of Uttar Pradesh, Sri N.N. Upadhyaya, Principal Secretary, Department of Science and Technology, U.P.; Sri D.C. Lakha,



Industrial Development Commissioner, U.P. and Sri Narendra Bhooshan, Executive Director, Udyog Bandhu, U.P. were nominated. The State government also nominated a biotechnology specialist, Dr. P.K. Seth, Chief Executive Officer Biotech Park & Former Director, Industrial Toxicology Research Centre, Lucknow in this

delegation.

Three basic objectives as decided and given by the Government of Uttar Pradesh to the delegation were: visit to various institutions, organizations, companies in Boston with CII as a part of its 6th Biotechnology Mission from

3rd May to 6th May, 2007, participation in International Biotechnology Convention and Exhibition - Bio-2007 organized at Boston from 7th to 9th May under the umbrella of India Pavilion and meetings with NRIs at Chicago, Illinois from 10th to 12th May, 2007.

It is pointed out that in order to reduce the costs involved in research & development and manufacturing of drugs as well as in undertaking clinical research, the western world is looking towards India because of its trained human resource and infrastructure. There are certain diseases which occur only in Asia and countries in this region and significant naïve population not exposed to any drugs because of these factors several drug companies are interested to invest in basic and clinical research in India and it is becoming a favourable destination of clinical research. In the field of Agribiotechnology, India also offers several opportunities and the country has established its ability and demonstrated its capability to absorb recent biotechnology advancements in this field. India is now growing several varieties of cotton containing BT gene and has surpassed China in growing BT cotton this year. Several institutions all over the country including research laboratories at Lucknow are working in the field of Agribiotechnology. A new genetically modified cotton variety containing BT gene has been developed at National Botanical Research Institute, Lucknow. Several companies are looking forward for partnership in the Agribiotechnology area.

In spite of the strong biotechnology base in the field of Agri - Medical biotechnology, Uttar Pradesh has not been able to attract much of the investment in the field of biotechnology while Karnataka, Andhra Pradesh and Maharashtra have been attracting number of foreign investors and their companies are now located in Bangalore, Hyderabad and Pune. The companies abroad are not fully aware about the strengths and infrastructure available in Uttar Pradesh because possibly in past, an effective presentation of these facts was not made at international level. **One of the major objectives of this delegation was to generate awareness and convince prospective investors that along with Bangalore, Hyderabad and Pune, Uttar Pradesh is also developing as a new hub for biotechnology in North India with its chain of laboratories and top class research institutions located in and around Lucknow.**

International Biotechnology annually Convention and Exhibition being held in USA and organize by Biotechnology Industry Organization, U.S.A. In different major cities of U.S.A. attracts a large number of exhibitors, research scientists and officials



related to science and biotechnology. For the last 5 years, CII has been organizing a Biotechnology Mission to U.S.A. to participate in this Global Convention and interact with selected institutions and organizations. This year, 6th CII Biotech Mission to USA was organized under the patronship of Dr. M.K. Bhan, Secretary, Department

of Biotechnology, Government of India who was also Chief figure of India Pavilion at Bio-2007 at Boston. The basic objective of the CII mission was to interact and network with various institutions and organizations such as Massachusetts Institute of Technology (MIT), Harvard University and premier companies like Millennium Pharmaceuticals, Genzyme, Novartis, Biogen Idec, etc. located in Cambridge and Boston, Massachusetts and also to participate in Bio-2007, an International Biotechnology Convention and Exhibition.



The U.P. delegation included Dr. P. K. Seth, CEO, Biotech Park, Lucknow; a National Figure in the field of Biotechnology so that the U.P. delegation could have discussions and interactions at all levels with superior intelligence and gives some fruitful technical output. The delegation also visited Chicago, Illinois, USA, another major Biotech City which has a number of research institutions and biotech industries for the said purpose.

The activity of the delegation began from May 3, 2007 and ended on May 9, 2007 at



Boston. Since the delegation was a part of CII Mission, the mission programme as was circulated by CII along with a booklet entitled “ 6th CII Biotechnology Mission to U.S.A., 3rd – 9th May, 2007: Boston ” published by CII containing brief bio-data of participating members

and their organizations (**Annexure 1**) was adhered to. Besides participating in discussions and interactions with prospective entrepreneurs, the delegation had full advantage of distributing copies of U.P. Biotech Policy, 2004; Highlights of U.P. Industrial Development Policy; Brochures specially prepared for this event by Biotech Park, Udyog Bandhu and Council of Science & Technology and CD and other materials as given in (**Annexure2**) on all occasions. It is further emphasised that all delegation members while introducing themselves on each occasion, also gave full details of the steps taken by the State Government of Uttar Pradesh to promote biotechnology in the state. In brief the delegation spent four days from 3rd to 6th May, 2007 along with CII and remaining three days from 7th to 9th May, 2007 in BIO-2007 at Boston and two days from 10th to 11th May, 2007 at Chicago. The details are as under:-

1. Networking Meeting at Millennium Pharmaceuticals, Cambridge

(03.05.2007)

Dr. Scott Brown, Vice-President of Millennium Pharmaceuticals, Inc welcomed the Indian delegation and informed that this company was founded in 1993 and it is one of the world's top biopharmaceutical companies. They have an excellent programme in the field of oncology and have developed Velcade, a drug for treatment of multiple myeloma. He also informed that they are looking for partnership in India. Dr. Sridhar Mosur, President and CEO, Jubilant Biosciences, India highlighted the achievements made in biotechnology industry in India and various incentives being provided by the Indian Government. He said that the country has brought new regulatory norms which will help in international research and industrial partnerships. Further to encourage partnerships, Department of Biotechnology, Government of India is catalysing setting up of specified zones and has also set up Biotech Parks. The Government of India has also announced Small Business Innovative Research Initiative (SBIRI) grants which can be availed by the industry to exploit their new technologies or for perfecting the technologies developed by research institutions and universities. **During the networking session, the members of the Uttar Pradesh delegation interacted with the senior management members of Millennium Pharmaceuticals and informed them about the U.P. Industrial and Biotech Policy and the facilities and incentives announced for promotion of biotechnology in the State.** Ms. Susan Finston, Executive Director, American Bioindustry Alliance,

Washington, DC in a brief address informed about the opportunities for research and business partnership between America and India.

2. Discussions with Chilean Delegation (03.05.2007)

Like Indian delegation, a contingent of about 100 scientists, administrators and entrepreneurs participated in Bio-2007 as a Chilean delegation. A meeting with the delegation was organized at Massachusetts, USA. Ms. Gloria Maldonali, Investment Programme Coordinator of the Chilean Economic Development Agency welcoming the Indian delegation mentioned that they are looking forward to learn from Indian experiences in Biotechnology and share their expertise. She said that there are enormous opportunities in the development of biotechnology in Chile which can be exploited jointly. She briefly described about the initiatives taken by the Chilean Government and the modern technology infrastructure available in Chile. Sri Ramesh Adige, Executive Director, Ranbaxy, India highlighted the progress made in Indian Biotechnology Sector and opportunities which exist in the field of Biotechnology for collaboration and joint ventures. **The brief addresses by different members of the Chilean and Indian delegations were followed by interaction on business opportunities and how to move forward.**

3. Visit to Biogen Idec Facilities, Cambridge (04.05.2007)

The company spends about 30% of its revenue towards research and development as it recognizes that a new drug is scientific discovery. Over the next five years the company proposes to spend about US \$5 billion on research and development. Their thrust is to find a cause for multiple sclerosis – a disease which leads to nerve degeneration.

The company has a global set up. It has its offices/ research laboratories in 25 countries which include Europe, Japan, China, New Zealand and Brazil. They have recently set up Biogen Idec Biotech India Pvt. Ltd. in Gurgaon and propose to expand that. Dr. Alpana Seth who is currently working in the company in U.S.A. would be heading the India operations. Over the next few years they propose to set up their R&D and manufacturing facilities. The delegation members interacted with her and other senior management members of the company and apprised them of the opportunities and possible advantages in the state

of Uttar Pradesh for setting up of research and development and manufacturing facilities.

In order to create awareness and interest in the field of biotechnology with a goal to enhance science literacy of students and general public, the company has set up community laboratories within its research buildings. These laboratories are open to local middle and high school students and teachers. Such laboratories are located in company head quarters in Cambridge, Massachusetts in an area of 1,100 sq. ft. and research campus in San Diego, California in an area of 1,300 sq. ft. The programmes are run at no cost basis to the community.

**4. Networking Meeting with Genzyme Company, Cambridge
(04.05.2007)**

A luncheon networking meeting was organized at Genzyme Company. Mr. P.K. Tandon, Vice-President, Global Biomedical Operations of Genzyme Company informed that the company is working in selected areas like cancer and multiple sclerosis. **The products of Genzyme Corporation are being sold in nearly 19 countries. The company's products and services are focussed on rare inherited disorders. Dr. Tandon said that they would be interested to explore the options of setting up their operations in Uttar Pradesh. The company is looking for space for setting up their office and laboratories in Gurgaon area. The members of the U.P. delegation informed that U.P. is developing as a biotechnology hub in the northern part of India and Lucknow has a number of research laboratories in the area of drug development, safety evaluation and clinical trials. Dr. Tandon said that company would keep this in mind and approach U.P. Government in near future.**

5. Visit to Novartis Research Centre, Cambridge (04.05.2007)

Novartis Institutes for Biomedical Research is also located in Cambridge, Massachusetts, USA and is the nerve centre for the development of various products which are in world wide market. Dr. Jeff Elton, Senior Vice-President and Chief Operating Officer welcomed the Indian delegation. Dr. Abbie C. Celniker, Global Head of Novartis and other officials addressed the delegation. From Indian side, Mr. Gautam Thappar, Chairman, CII and also Chairman of the National Committee on Biotechnology & Chairman,

Ballarpur Industries Limited, while delivering the opening remarks said that this time we have a large Indian delegation which shows the interest of Indian industry and academia to collaborate and undertake joint research and bio business with U.S. companies. Dr. Rashmi Barbhaiya, CEO & MD, Adventis Therapeutics speaking on behalf of the Indian biotech industries highlighted that the country has made outstanding performance in the field of biotechnology. Consistently during the last three years, there has been an all round growth of 30-35% in various fields of biotechnology. **During the interactive sessions, U.P. delegation informed about the new initiatives taken by the State in formulating industry friendly Industrial and Biotechnology Policies and setting up an NRI cell to help the NRIs in setting up their business in the State.**

6. CII Conference “ Indo-US Business Opportunity in Biotechnology” (04.05.2007)

This event was held at Hotel Boston Marriot, Boston and was well attended by about 100 participants including U.S. industrialists, NRIs, officials of Indian embassy and others who had expressed their interests to interact with the Indian delegation to explore the research and business opportunities. Mr. Gautam Thappar, Chairman, CII while delivering the opening remarks said that India is looking forward for a close interaction with U.S.A. and wishes to share the advancements made in the field of biotechnology. Dr. Sridhar Mosur, President and CEO, Jubilant Biosciences, India in his special address highlighted the progress made in the biotech industry and business opportunities in India. The panel members, Dr. Rashmi Barbhaiya, CEO & MD, Adventis Therapeutics; Dr. Viloo Morawala Patell, Vice Chairperson & MD, Avesthagen; Dr. M. Vidyasagar, Executive Vice President, TCS and Dr. Ramesh Adige, Executive Director, Ranbaxy Laboratories highlighted the opportunities in the field of drug development, agri-biotechnology and bioinformatics. Partner State for this event was Andhra Pradesh and on behalf of Andhra Pradesh Government, Dr. Deepanwita Chattopadhyay, CEO of ICICI Knowledge Park, Hyderabad informed about the progress made in the field of biotechnology in Andhra Pradesh in the Genome Valley. She informed that more than 19 companies are functioning in ICICI Knowledge Park and S.P. Biotech Park, another prestigious park located at Hyderabad. These parks are promoting manufacturing and R & D activities. Novartis has already

acquired about 20,000 sq.ft. Land in S.P. Biotech Park. She also informed that Andhra Pradesh Industrial Development Corporation has setup a Venture Capital of 50 million rupees and is also providing separate funds for early stage companies.

The meeting was also addressed from the US side by Dr. Danielle Bosley, Chairman, Economic Development Committee, Government of U.S.A and Dr. Holly Vineyard, Deputy Assistant Secretary, Department of Commerce, Government of U.S.A.

Dr. M.K. Bhan, Secretary, Department of Biotechnology, Government of India delivering the keynote address said that the country is giving high priority for developing world class human resource. He said that approval for setting up of new universities are being granted and programmes for masters and Ph.D. programmes are being pursued in the field of medical biotechnology. Numbers of new institutions are being created and an Institute for Translation Research is also being setup. Government of India is promoting setting up universities and institutions under public-private partnership to promote platform for technology and expand opportunities in human resource. Several states like Gujarat, Orissa, Uttaranchal & U.P. are setting up Biotech Parks and promoting biotechnology. International collaboration in the field of bioengineering and translation research is being made and an MOU has been signed with NIH and Stanford University. A Biotechnology Regulatory Authority on the lines of food and drug administration is being set up and the significance of regulation is being recognized at the highest level of governance. The country has launched 24 major national projects and 13 transgenic crops have been developed. There has been a significant increase in the science budget and the Government is providing several incentives for expenditure and research.

The members of the U.P. delegation interacted with the participants of this meet. Several people expressed their interests in exploring the possibilities of collaboration with the institutions in Lucknow and Biotech Park at Lucknow. **Dr. Charles L. Conney, Prof. of Chemical and Biochemical Engineering and Faculty Director, Deshpande Centre for Technological Innovation of MIT, Boston expressed great interests in learning more about the**

activities of Lucknow laboratories. Some young scientists who are currently pursuing their research at Harvard University expressed their interest to explore the business opportunities in Lucknow.

7. **MIT-India Conference “Tales from the Cutting Edge: Biotechnology and Life Sciences in India and at MIT (Massachusetts Institute of Technology), Boston” (05.05.2007)**

Participation in this session was highly rewarding and an enriching experience. The programme was organized by Massachusetts Institute of Technology (**Annexure 3**). Dr. Thomas L. Magnante, Dean of Engineering, MIT in his opening remarks mentioned that MIT has 100 years of association with India. The American Society of Engineering and Education has undertaken several programmes. About 50 courses are being run in the institute in which a large number of Indian students participate. He said that we regard India with great respect and look forward for our continued collaboration. Mr. Gautam Thappar, Chairman, CII mentioned that there are proposals from the CII for collaboration in the area of marketing and other services. Dr. Sanjay Mittal, MIT Professor delivering the introductory address for the MIT Conference, said that our India programme has benefited students and faculty at MIT as well as India and some social goals have been achieved. The dialogue which we are having today will help us further. A visit of the President of MIT is being planned to Indian institutions specially to study the Indian education system. He said that there is a need to change the primary and higher learning systems and also to study that how the Indian universities can be engaged with industries. Further, there is a need to exploit the technology in India for elevating poverty and education.

Session-I on Innovation in Technology and Industry: Challenges and Achievements was a very interesting session. Dr. Vijay Chandru, CEO, Strand Life Sciences, Bangalore, India in his introductory remarks said that his company is now mostly working for *in silico* life sciences. The company has developed an *in silico* human liver. Dr. Chandru is a graduate of MIT from where he moved to Indian Institute of Science, Bangalore and subsequently formed two companies in India which are highly successful in the field of bioinformatics.

Dr. M. Vidyasagar, Executive Vice President, Tata Consultancy Services (TCS), India, a graduate of MIT spoke about the success made by the Tata Consultancy Services Group in the field of bioinformatics. He said that Shantha Biotech has developed Hepatitis B Vaccine which has led to 80% reduction in the cost. TCS is working closely with many companies to address the challenges and opportunities related to post genomic diseases, malaria, tuberculosis, and diabetes. The company is helping in identifying drug targets for malaria which are in form of unique genes for the Falciparum species. Prof. Subra Suresh, Professor in Department of Material Sciences and Engineering, MIT highlighted the work being carried out in his department and the opportunities which exists in the field of material sciences. Dr. Arun Chandravarkar, Chief Operating Officer, Biocon, India, a MIT graduate, said that Biocon is a 250 million dollar company and made 50 million dollar profit. His company is incurring lot of expenses for new discovery.

The session-II on Innovation and Education: Empowering the Teachers was equally interesting. In this session the MIT Professors, Dr. Arvind, Dr. M.S. Vijay Kumar and Dr. George C. Verghese shared their views and informed that MIT in collaboration with number of institutions has developed open education resources. They informed that collaborative teaching programmes are being developed with IIT's of Madras, Delhi and Kanpur. It was also informed that MIT has visiting committees which guide them for developing curriculum which would promote entrepreneurship among the students.

In the Session-III on Innovation and Health Initiatives: New Frontiers, Dr. Shiladitya Sengupta, HST Affiliated Faculty, Harvard-MIT Health Sciences, spoke on the public health and other areas being pursued by his group. Dr. M.K. Bhan, Secretary, Department of Biotechnology, Government of India informed about the progress made by Indian Biotech industry and also the opportunities which exist for collaboration in the modern medical biotechnology areas. He said that Department of Biotechnology, Government of India has taken several steps for promoting high quality medical research for which new institutes are being set up with the participation of other departments and private institutions. He explained in detail the concept of setting up an institution which will be having a Centre for Translation Research and UNESCO Centre for education and training in biotechnology.

These will be working together and the institution will have technical / scientific platforms for large scale sequencing, genetic analysis, proteomics, RNA- imaging, etc. It will also have animal house, library, auditorium, conference facility and there will be extra mural setup for undertaking clinical trials, regulatory support, IPR management and technical training. He said that the Government is fully aware of the need for highly skilled manpower both at the research and technical level and we are entering into MOUs with Massachusetts Institute of Technology and National Institutes of Health, U.S.A and other such institutions.

8. Visit to Charles River Laboratories, Inc.date (May 6th , 2007)

The Charles River Laboratories, Inc. has setup new facilities for drug discovery, safety evaluation and toxicity testing. Dr. Paul A. Oscar III, Corporate Vice president, Charles River Laboratories gave an overview of the Charles River Laboratories activities and the newly built facilities. This was followed by a visit of the members of the delegation to their drug discovery, safety evaluation and toxicity testing facilities. Their facilities are excellent and are recognized by FDA and other institutions.

Dr. P.K. Seth, Chief Executive Officer, Biotech Park, Lucknow informed about the facilities available at Biotech Park, Lucknow which is a joint venture of Government of India and Government of Uttar Pradesh and suggested that Charles River Laboratories may consider setting their toxicity testing facility in an appropriate place in Uttar Pradesh. The management said that we propose to visit India in near future and would like to include Uttar Pradesh in our visit.

9. International Biotechnology Convention and Exhibition (07.05.2007 to 09.05.2007)

The U.P. delegation actively participated in the scientific exhibition and conference from May 7 to 9, 2007 held at the Boston Convention and Exhibition Centre, Boston, Massachusetts. This was an important global event in biotechnology organized by the Biotechnology Industry Organization, U.S.A and was attended by 22,366 delegates from 64 countries all over the world. About 900 companies from 39 countries set up pavilions in the exhibition hall representing every aspect of biotechnology industry.

An Indian Pavilion was put up in the Exhibition Hall. Besides the Department of Biotechnology, Government of India, Council for Scientific and Industrial Research and several State Governments like Karnataka, Gujarat, Maharashtra, Andhra Pradesh, Himachal Pradesh, several top biotechnology industries especially from Pharma- and Agri- Biotechnology also had their presence. The U.P. Government also participated in the Pavilion by having a stall where posters, brochures, copies of related materials as given in **Annexure** distributed. **On an average about 300 to 400 persons visited India Pavilion and several of them showed their interest in Uttar Pradesh and many specially NRIs expressed their surprise to see that Uttar Pradesh is also growing in the field of Biotechnology and interestingly a Biotech Park has already come up in Lucknow.**

10. Discussions with International Biotechnology Investment Corporation, MA, USA

At the initiative of Dr. P.K. Seth, CEO, Biotech Park, Lucknow and at the invitation of the International Biotechnology Investment Corporation, MA, USA, the delegation had meetings and discussions with the senior official of Corporation. on May 7th and 8th, 2007 the corporation was represented by Mr. J. N. Seth, President and CEO, International Biotechnology Investment Corporation, MA, USA, Mr. Steven A. Kessler, Senior Executive Vice President, International Biotechnology Investment Corporation and International Planning & Development, Mr. Paul J. Woods, Vice President, Real Estate and Mr. Ian B. Blumenstein, Member of the Firm Proskauer Rose LLP. **The Corporation has an ambitious plan to create a Biocluster in Lucknow, Uttar Pradesh on 1000 acres of land. This would include a world class Research and Development facility for research on all aspects of Biotechnology covering agriculture, plants, animals, pharma & biomolecular medicine, energy, environment & industrial biotechnology in the shape of Institute of Biotechnology. This institute would help in generating the skilled human resource specialities to cater to Research and Industry through high quality biotechnology courses. It would also provide facilities for undertaking cutting edge research on the frontiers of biotechnology and develop novel products and technologies. Their proposal further aims to setup Biotechnology Clusters in the form of number of industrial units.**

This Corporation is extremely interested in developing Biotech Clusters and an Institute of Biotechnology. They propose to undertake this venture in a period of 10 years with an investment of about 2-3 billion dollars. **They requested the U.P Delegation to consider provision of at least 1000 acres of land on a free hold basis on Lucknow – Kanpur road. The Corporation is developing a Bio-Ready Site in Andover, Massachusetts, USA in about 100 acres of land.**

Discussions and deliberations in detail on the project took place and a positive response was given to the corporation by Industrial Development Commissioner, U.P. subject to clearance by top level in Government.

11. Chicago Chapter (10.05.2007 to 11.05.2007)

Sri Chandra S. Trivedi, President of U.P. Association of Scientists at Chicago, organized a meeting with NRIs on **May 10, 2007**. The meeting was attended by about 30 persons. The acting Consulate General of India with HQs at Chicago, Mr. Jagdish Rai also attended the meeting. Prominent among



the participants were Mr. Ajeet Pant, Financial Planner of the Preferred Planning Group, Dr. Anil Gulati of Oxygen Therapeutics Inc., Dr. Ghanshyam N. Pandey, Professor of Pharmacology, Department of Psychiatry, University of Illinois at Chicago, Dr. Bellur S. Prabhakar, Professor and Head, Department of Microbiology & Immunology, University of Illinois at Chicago and Mr. Roshan Lal Goel of Metlife, Chicago. **They were enthusiastic to know about the developments in the field of Biotechnology in Uttar Pradesh and the facilities being offered by the Government of Uttar Pradesh to the NRIs interested in setting up of their R&D units.**



Sri Narendra Bhooshan, Executive Director, Udyog Bandhu explained in detail the new initiatives of state government, which included setting up of a NRI cell. He explained that ED UDYOG Bandhu is the Nodal Officer for this NRI cell. **The objectives of**

NRI cell include providing a single window to NRIs for their all types of issues ranging from any type of law & order problem with respect to their relatives back in UP, protecting their property and helping them invest in UP. Thus this NRI cell proposes to serve as an important link between NRIs and their mother land. He also explained other policies like the Industrial Policy of the Government of Uttar Pradesh and the incentives being provided to the entrepreneurs.

There was an overwhelming response from all NRIs and lot of discussion took place about NRI cell. Everyone gave few suggestions for efficient functioning of NRI cell. One of major demand was the regular visit by High level delegations from UP. Like the practice adopted by other Indian states. They explained how Southern Indian states have much more contact and interaction with their counterparts and suggested that instead of seeking investment, UP govt. should use NRI's intellectual wealth, in increasing the standard of Engg colleges, Medical colleges and other educational institutions. They said they are ready to provide their services free of cost, for the sake of their motherland. There was a suggestion of making a web based platform, where NRIs can interact with state



Government as well as NRIs of other places. There should be a forum where NRIs can give suggestions about development of UP. Sri N.N. Upadhyaya, Principal Secretary,

Department of Science and Technology, U.P. and the leader of the delegation informed them that the State has announced a Biotech Policy and the subject is receiving great attention in the State. He also informed that Government of Uttar Pradesh has setup a Biotech Park in Lucknow with the support of Department of Biotechnology, Government of India and it proposes to setup more such parks in other parts of the state focussing on the bio resources and infrastructure available. Dr. P.K. Seth, Chief Executive Officer, Biotech Park, Lucknow briefly described about the unique features of Lucknow Biotech Park and the incubator facilities developed during the last three years at the Biotech Park. NRIs had several other queries with respect to Industrial Policy and availability of land which was answered by Sri D.C. Lakha, Industrial Development Commissioner, U.P. Sri Lakha also provided them copies of the brochure containing the Industrial Policy of the State Government. Mementos as token of remembrance on behalf of NRI cell were presented to Consulate general, Dr Ghanshyam Pandey, the convener, the president and other prominent NRIs. **Dr. Gulati, Mr. Gupta and Prof. Pandey proposed to visit India within next 3-4 months and explore the possibilities of undertaking some joint ventures.**



On May 11, 2007, Prof. Ghanshyam Pandey, the President of the Neuroscience Division of Association of Scientists of Indian Origin in America (ASIOA) organized a meeting of the delegation with NRIs at Department of Psychiatry, University of Illinois at Chicago. This meeting was attended by about 25 participants. Prominent among them were Dr. Durisala Desai of Eli Lilly and Company, Indianapolis; Dr. Harish C. Pant of National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Dr. Syed F. Ali, Senior Biomedical Research Scientist of National Centre for Toxicological Research / FDA and Dr. Dipak Sarkar, Distinguished Professor and Director of Endocrine Program and Biomedical Division, State University of New Jersey, U.S.A.

Dr. Durisala Desai informed that he is regularly visiting India in connection with his work and is interested to expand his business activities in Northern India and during his next visit he will explore the possibility of setting up some of his units in



North India. Dr. Prabhakar and Dr. Sarkar said that they have developed some new animal models for neurosciences research and testing as well as some unique molecules for certain neurological disorders and are interested in undertaking collaborative research with some top institutions in Northern India as well as setup small laboratories for testing the efficacy with some industries in India. The delegation was also invited to interact with the participants of a one day National Scientific Conference on “The Expanding Frontiers of Neurosciences” during which a Special Session on “Science and Technology Initiative in Uttar Pradesh, India” was also organized.

It’s worthwhile to put on record that Sri. N.N. Upadhyaya, Principal Secretary, Department of Science and Technology, Government of Uttar Pradesh and Dr. P.K. Seth, CEO, Biotech Park, Lucknow were key speakers during special session. A copy of the programme on the said conference is annexed. (*Annexure*). Sri N.N. Upadhyaya informed the participant NRIs about the Biotech Policy of U.P. Government and other initiatives taken by U.P. Government to promote biotechnology industries and to help the NRIs and local entrepreneurs to set up their bio business. Sri D.C. Lakha and Sri Narendra Bhooshan interacted with the potential NRI entrepreneurs and investors. Dr. P.K. Seth using a PowerPoint presentation described the incubator facilities available at Biotech Park, Lucknow and the facilities available in various CSIR and ICAR laboratories in Lucknow which could be utilized by NRI entrepreneurs. **The participant NRIs said that they are extremely delighted to know that State has taken new initiatives for the promotion of biotechnology and a Biotech Park has been setup in Lucknow. Expressing happiness about the progress made by UP in biotechnology they said that so far they knew that biotechnology is**

progressing only in Southern States of India because in those states respective governments are providing initiatives to entrepreneurs. They assured that they would certainly explore the possibility and visit Uttar Pradesh to discuss the business plans and avail the existing facilities in the local institutions and the Biotech Park. The above conference was followed by a reception given in the honour of U.P. Delegation which too was attended by several other NRIs of Illinois area.

Specially prepared folders containing all relevant materials were distributed on all above three occasions.

Recommendations

1. NRI cell should be made more functional and single point shop for interaction with NRIs.
2. There should be regular visits by high level delegations to have interactions with NRIs.
3. There was demand that Hon'ble CM should lead the future delegation. People fondly remembered that She had visited USA in her last tenure as CM and invited them to invest in UP.
4. NRIs wanted a comprehensive website of NRI cell should be developed, which acts as the platform for interaction with state governments and among themselves.
5. There should be constituted a forum consisting of NRIs, which can give suggestions for the development of UP.
6. In NRI cell, there should be a system, where NRIs visiting the state can visit and interact with Government officials.
7. The suggestions given by NRIs should be followed up properly and answer sent to them about the action taken. This can be displayed on the website
8. NRI can contribute more by way of their intellectual strength, rather than financial investment.
9. They are ready to share their experiences/ with educational institutes of UP to bring them at par with world level institute. There should be a mechanism to do it.

Annexure

No.	Annexure	Pages
1.	Scientific Programme of 6th CII Biotech Mission to USA	7
2.	Catalogue containing information about participants and organizers	48
3.	CII Conference “ Indo-US Business Opportunity in Biotechnology	1
4.	Programme- MIT-India Conference “Tales from the Cutting Edge: Biotechnology and Life Sciences in India and at MIT”	1
5.	Pocket Guide – Bio International Convention	19
6.	India Pavilion Exhibitor’s Guide	30
7.	Details of Contacts made with prospective Entrepreneurs and dignitaries	20
8.	Material Distributed by the Members of the Delegation during the visit <ul style="list-style-type: none"> • C.D. (containing information about Biotech Policy, U.P.; Department of Science and Technology, U.P.; Council of Science and Technology, U.P.; Strengths of U.P. with emphasis on Lucknow) • C.D. PREPARED BY Udyog Bandhu • U.P. Biotech Policy- 2004 • Pamphlets & Brochures on Biotech Park, Lucknow; NRI cell, Industrial Policy, Udyog Bandhu ,incentives and concessions by U.P. Government 	